Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Gynecologic 1

Conditions

Precancerous Conditions 3Neuroblastoma 3Skin Neoplasms 2Prostatic Neoplasms 2Carcinoma, Basal Cell 2Adenomatous Polyposis Coli 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Non-melanoma Skin Cancer 1Keratosis, Actinic 1Gastritis, Atrophic 1Esophageal Neoplasms 1Colorectal Neoplasms 1Adenomatous Polyps 1

Interventions

Cisplatin 72Brachytherapy 31Radiotherapy 26Paclitaxel 23Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 21human papillomavirus vaccine, L1 type 16, 18 20Topotecan 18Papillomavirus Vaccines 18Carboplatin 18Surveys and Questionnaires 17Bevacizumab 16pembrolizumab 14Radiation 12Gemcitabine 12Early Intervention, Educational 12Colposcopy 12Methods 11Magnetic Resonance Spectroscopy 11atezolizumab 10Radiotherapy, Intensity-Modulated 10Blood Specimen Collection 10Papanicolaou Test 9Docetaxel 9Vaccines, Synthetic 8Platinum 8Nivolumab 8Ipilimumab 8Counseling 81,2-diaminocyclohexaneplatinum II citrate 8Vaccines 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Uterine Cervical Neoplasms × Eflornithine × Clear all
NCT00006079 2018-10-25

Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

M.D. Anderson Cancer Center

Phase 2 Completed
150 enrolled
GynecologicOther neoplasm

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡